Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT01799083
Show Display Options
Rank Status Study
1 Recruiting Lower Dose Decitabine Based Therapy in Patients With Refractory and/or Chemotherapy Resistant Solid Tumors or B Cell Lymphomas
Conditions: Solid Tumors;   B Cell Lymphoma
Interventions: Drug: Decitabine;   Biological: cytokine-induced killer cell

Indicates status has not been verified in more than two years